Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;9(3):233-240.
doi: 10.1007/s40336-021-00419-y. Epub 2021 Mar 11.

Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review

Luca Giovanella  1   2 , Rosaria M Ruggeri  3 , Petra Petranović Ovčariček  4 , Alfredo Campenni  5 , Giorgio Treglia  1   6   7   8 , Desiree Deandreis  9
Affiliations
Review

Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review

Luca Giovanella et al. Clin Transl Imaging. 2021.

Abstract

Purpose: Currently, there is an increasing interest regarding the impact of COVID-19 on the thyroid function. As several recent reports have described the onset of thyroid dysfunction in patients diagnosed with COVID-19, we performed a systematic review to assess the prevalence of thyroid dysfunction in patients with COVID-19 as this information could be clinically relevant for the management of these patients.

Methods: A comprehensive computer literature search using PubMed/Medline and Cochrane databases was performed until November 14, 2020 to search original articles evaluating thyroid dysfunction in COVID-19 patients. Information about thyroid dysfunction assessed by thyroid function test was retrieved by the eligible articles. Qualitative analysis (systematic review) only was performed whether a significant heterogeneity of data was detected.

Results: Seven studies including 1237 patients with COVID-19 were included. A significant heterogeneity across the studies was found. Most COVID-19 patients were euthyroid with TSH levels in the normal range (from 44 to 94% of the COVID-19 patients assessed in the included studies). The prevalence of thyroid dysfunction in COVID-19 patients (defined as abnormal thyroid function tests) largely varies among the included studies between 13 and 64% of COVID-19 patients as well as clinical presentation. A positive correlation between thyroid dysfunction and clinical severity of COVID-19 was reported.

Conclusion: Literature data show that thyroid dysfunction is present in a significant percentage of patients with COVID-19. Assessment of thyroid function may be considered in symptomatic COVID-19 patients to have a baseline before introducing thyroid-interfering drugs and those requiring high-intensity care. Further, well-designed studies are needed to better elucidate the impact of COVID-19 on thyroid function and inform thyroid function testing and thyroid dysfunction management in COVID-19 patients.

Keywords: COVID-19; SARS-CoV-2; Systematic review; TSH; Thyroid; Thyroid dysfunction.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestLG is a member of the Roche Diagnostics advisory board and has received research grants and speaker honoraria from Roche Diagnostics, IBSA, and Sanofi-Genzyme. Other Authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
ACE-2 receptors in thyroid follicular cells and SARS-CoV-2 entry
Fig. 2
Fig. 2
Flow chart of the search for eligible studies on thyroid dysfunction in COVID-19 patients
See this image and copyright information in PMC

References

    1. Hossain MF, Hasana S, Mamun AA, Uddin MS, Wahed MII, Sarker S, et al. COVID-19 outbreak: pathogenesis, current therapies, and potentials for future management. Front Pharmacol. 2020;16(11):563478. doi: 10.3389/fphar.2020.563478. - DOI - PMC - PubMed
    1. Parolin M, Parisotto M, Zanchetta F, Sartorato P, De Menis E. Coronaviruses and endocrine system: a systematic review on evidences and shadows. Endocr Metab Immune Disord Drug Targets. 2020 doi: 10.2174/1871530320666200905123332. - DOI - PubMed
    1. Marazuela M, Giustina A, Puig-Domingo M. Endocrine and metabolic aspects of the COVID-19 pandemic. Rev Endocr Metab Disord. 2020;21(4):495–507. doi: 10.1007/s11154-020-09569-2. - DOI - PMC - PubMed
    1. Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2020;6:1–6. doi: 10.1007/s40618-020-01436-w. - DOI - PMC - PubMed
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;2009(339):b2535. doi: 10.1136/bmj.b2535. - DOI - PMC - PubMed

LinkOut - more resources